Kitov Pharma (KTOV) Reports Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy
Tweet Send to a Friend
Kitov Pharma Ltd. (NASDAQ: KTOV), an innovative biopharmaceutical company, today announced positive results in a pre-clinical study testing NT219, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
